T1	Participants 561 570	patients.
T2	Participants 379 387	patients
T3	Participants 620 628	patients
T4	Participants 1275 1324	44 patients to combination and 45 to single agent
T5	Participants 1326 1340	Eight patients
T6	Participants 1376 1391	combination arm
T7	Participants 1426 1442	Treatment groups
T8	Participants 1577 1586	29 trials
